

Avelox[®] (moxifloxacin) – First-time generic

- On October 5, 2017, Mylan launched an AP-rated generic version of Bayer's Avelox (moxifloxacin) • 400 mg injection.
- Avelox is approved for the treatment of community acquired pneumonia, complicated and • uncomplicated skin and skin structure infections, complicated intra-abdominal infections, plague, acute bacterial sinusitis, and acute bacterial exacerbation of chronic bronchitis.
 - Refer to Avelox's drug label for specific susceptible isolates covered for each indication.
- Avelox is also available generically as a 400 mg oral tablet. •



optumrx.com

OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at optum.com.

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2017 Optum, Inc. All rights reserved.